C4 Therapeutics (CCCC) Operating Expenses (2019 - 2026)
C4 Therapeutics has reported Operating Expenses over the past 8 years, most recently at $33.9 million for Q1 2026.
- For Q1 2026, Operating Expenses fell 6.77% year-over-year to $33.9 million; the TTM value through Mar 2026 reached $148.7 million, down 4.89%, while the annual FY2025 figure was $151.2 million, 2.6% down from the prior year.
- Operating Expenses for Q1 2026 was $33.9 million at C4 Therapeutics, down from $34.2 million in the prior quarter.
- Over five years, Operating Expenses peaked at $45.6 million in Q3 2025 and troughed at $33.4 million in Q2 2024.
- A 5-year average of $38.9 million and a median of $39.2 million in 2022 define the central range for Operating Expenses.
- Biggest five-year swings in Operating Expenses: skyrocketed 39.69% in 2022 and later decreased 20.34% in 2025.
- Year by year, Operating Expenses stood at $41.1 million in 2022, then decreased by 1.12% to $40.7 million in 2023, then increased by 5.4% to $42.9 million in 2024, then dropped by 20.34% to $34.2 million in 2025, then dropped by 0.66% to $33.9 million in 2026.
- Business Quant data shows Operating Expenses for CCCC at $33.9 million in Q1 2026, $34.2 million in Q4 2025, and $45.6 million in Q3 2025.